Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intracoronary Cocktail Injection in FFR-Guided PCI for ACS
NCT02592720Phase 4Unknown
- Sponsor
- Xijing Hospital
- Start
- Oct 2015
- Primary completion
- Oct 2017
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of tirofiban, bivalirudin and tenecteplase in acute coronary syndrome (ACS) (2 arms), sponsored by Xijing Hospital. Primary endpoint: Major Adverse Cardiac Events at 1 year. Status: unknown.
02
Drugs
tirofibanbivalirudintenecteplase
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on NCT02592720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02592720.